Governors Lane’s Heron Therapeutics HRTX Stock Holding History

Governors Lane’s Portfolio HRTX Stock Details HRTX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q4	–	Sell	-200,000	Closed	-$6.33M	–	78
2018 Q3	$6.33M	Buy	+200,000	New	+$7.45M	0.35%	55

Other funds holding HRTX

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TCM

Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

ACH

ArrowMark Colorado Holdings Denver, Colorado $3.76B AUM 21.77% 1-Year Est. Return

Governors Lane's HRTX Position: Q1 2019 in Review

Governors Lane sold out of Heron Therapeutics (HRTX) in Q1 2019, closing a stake of 180,802 shares — an estimated $4.69M sold.

Governors Lane first reported a position in HRTX in Q3 2018 and held it in 2 quarters. The position peaked at $4.69M in Q4 2018. 198 funds tracked by Wall St. Rank hold HRTX as of Q1 2019.

Governors Lane reported no remaining Heron Therapeutics position as of Q1 2019 after selling out during the quarter.
Governors Lane sold 180,802 Heron Therapeutics shares in Q1 2019, an estimated $4.69M.
Governors Lane first reported a position in Heron Therapeutics in Q3 2018 and held it in 2 quarters.
Governors Lane's Heron Therapeutics position peaked at $4.69M in Q4 2018.
198 funds tracked by Wall St. Rank held Heron Therapeutics as of Q1 2019.

Based on Governors Lane's 13F filing for Q1 2019, filed 15 May 2019.